Although further in vivo studies, including dose-dependent toxicity and survival rate analyses, are necessary, this study suggests that the combination therapy of CDK4/6 inhibitors and antidepressants may represent a novel therapeutic approach for solid tumors such as colorectal, breast, and lung cancers. Here, CDK4 is linked to lung cancer.